US · MCRB
Seres Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02139
- Website
- serestherapeutics.com
Price · as of 2024-12-31
$7.61
Market cap 79.07M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $506.00 | ||||
| 2016 | $186.60 | ||||
| 2017 | $187.00 | $1,564.75 | $0.00 | $0.00 | $0.00 |
| 2018 | $102.20 | $40.88 | $0.00 | $0.00 | $162.60 |
| 2019 | $70.40 | $28.16 | $0.00 | $0.00 | $0.00 |
| 2020 | $427.40 | $170.96 | $18.24 | $0.00 | $0.00 |
| 2021 | $142.40 | $397.30 | $495,304.27 | $0.00 | $0.00 |
| 2022 | $105.20 | $8,222.77 | |||
| 2023 | $19.42 | ||||
| 2024 | $15.32 |
AI valuation
Our deep-learning model estimates Seres Therapeutics, Inc.'s (MCRB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $7.61
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MCRB | Seres Therapeutics, Inc. | $7.61 | 79.07M | — | — | — | — | 875.27 | 8.64 | — | -1.50 | 14208.58 | 8.64 | 0.00% | — | — | -0.88% | -241.20% | 0.05% | 6.65 | — | 0.94 | 0.86 | -0.51 | 616.00% | — | 1888.00% | -125.16% | -3.61 | -296.22% | 0.00% | 0.00% | 8.38% | -1.48 | -1.21 | — | -12.11 |
| ABOS | Acumen Pharmaceuticals, I… | $3.14 | 190.2M | — | — | — | — | -0.73 | 0.41 | — | 0.68 | -1.26 | 0.41 | 0.00% | — | — | -45.60% | -248.14% | -37.27% | 0.16 | -28.03 | 6.46 | 6.21 | 0.06 | 5833.00% | — | 10014.00% | -114.95% | -3.12 | -187.66% | 0.00% | 0.00% | 0.05% | 0.59 | 0.78 | — | -1.94 |
| ACTU | Actuate Therapeutics Inc | $3.74 | 86.93M | — | — | — | — | -4.97 | 1301.78 | — | -5.05 | -5.09 | 1301.78 | 0.00% | — | — | 54.83% | 45.28% | -443.16% | 0.00 | 1344.27 | 1.05 | 0.98 | 0.34 | 9758.00% | — | 101.00% | -16.10% | -2.48 | 39.31% | 0.00% | 0.00% | 4.19% | -5.05 | -5.81 | — | -19.92 |
| APLT | Applied Therapeutics, Inc… | $0.10 | 14.86M | +30,191% | +123% | — | +60,988% | -0.76 | 1.40 | 175.54 | -0.03 | — | 1.40 | 100.00% | -22922.86% | -23214.07% | -529.97% | 242.94% | -149.27% | 0.05 | — | 3.06 | 2.91 | 0.74 | -4648.00% | -9545.00% | 5280.00% | -105.55% | -3.09 | 196.37% | 0.00% | 0.00% | 34.41% | -0.03 | -0.04 | 7.18 | -10.84 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| HURA | TuHURA Biosciences, Inc. | $1.67 | 94.32M | — | — | — | — | -1.80 | 2.67 | — | -1.52 | — | 2.67 | 0.00% | — | — | -332.67% | 4773.62% | -178.25% | 0.01 | -4.26 | 3.68 | 2.42 | 0.71 | -8925.00% | — | 2291.00% | -37.91% | -2.76 | 3999.15% | 0.00% | 0.00% | 28.55% | -1.50 | -1.80 | — | -5.49 |
| INO | Inovio Pharmaceuticals, I… | $1.81 | 97M | +981% | -57% | — | +13,527% | -0.49 | 0.77 | 243.22 | 0.28 | — | 0.77 | 100.00% | -51616.91% | -49254.27% | -115.42% | 1958.18% | -75.49% | 0.17 | -632.05 | 2.77 | 2.70 | 0.52 | -3514.00% | -7383.00% | -1614.00% | -197.43% | -2.95 | 1821.69% | 0.00% | 0.00% | 131.88% | 0.26 | 0.28 | -134.48 | -23.30 |
| IRD | Opus Genetics, Inc. | $4.16 | 286.89M | +1,572% | -90% | — | +1,569% | -0.46 | 3.97 | 2.43 | 0.06 | -0.13 | 3.97 | 100.00% | -564.72% | -523.40% | -203.19% | 512.82% | -126.71% | 0.00 | — | 3.24 | 3.20 | 0.53 | 36739.00% | -4230.00% | 220000.00% | -95.73% | -2.26 | 211.29% | 0.00% | 0.00% | 0.30% | 0.06 | 0.14 | -0.33 | -9.18 |
| SEER | Seer, Inc. | $1.72 | 96.75M | +1,276% | +24% | — | — | -1.41 | 0.37 | 8.76 | 0.94 | -47.63 | 0.37 | 48.99% | -717.72% | -620.91% | -23.91% | -88.56% | -21.57% | 0.08 | — | 16.53 | 15.83 | 0.16 | 296.00% | -813.00% | -2513.00% | -40.66% | -3.01 | -43.96% | 0.00% | 0.00% | 18.30% | 0.88 | 1.78 | -6.33 | 0.30 |
| SPRO | Spero Therapeutics, Inc. | $2.17 | 122.26M | +1,351% | -86% | — | +2,434% | -0.61 | 0.91 | 0.88 | 0.09 | — | 0.91 | -101.67% | -152.91% | -142.91% | -89.62% | -436.22% | -46.81% | 0.09 | — | 2.19 | 2.15 | 0.67 | -39535.00% | -5377.00% | -2895.00% | -55.69% | -0.48 | -139.40% | 0.00% | 0.00% | 0.00% | 0.09 | 0.28 | -0.14 | -6.55 |
| VTGN | VistaGen Therapeutics, In… | $0.59 | 19.2M | +3,740% | +110% | — | +12,444% | -1.41 | 1.03 | 149.14 | 0.12 | -14.28 | 1.03 | 100.00% | -11517.08% | -10579.84% | -55.68% | 986.92% | -49.44% | 0.02 | — | 6.51 | 6.38 | 1.19 | 987.00% | -5432.00% | 6344.00% | -58.34% | -3.34 | 745.62% | 0.00% | 0.00% | 0.00% | 0.12 | 0.15 | -13.36 | -4.85 |
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
- CEO
- Thomas J. DesRosier
- Employees
- 103
- Beta
- 0.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $7.61) − 1 = — (DCF, example).